365 related articles for article (PubMed ID: 28507103)
1. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
[TBL] [Abstract][Full Text] [Related]
2. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
[TBL] [Abstract][Full Text] [Related]
3. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Olesen UH; Hastrup N; Sehested M
APMIS; 2011 Apr; 119(4-5):296-303. PubMed ID: 21492230
[TBL] [Abstract][Full Text] [Related]
4. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
[TBL] [Abstract][Full Text] [Related]
5. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
[TBL] [Abstract][Full Text] [Related]
6. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.
Duarte-Pereira S; Pereira-Castro I; Silva SS; Correia MG; Neto C; da Costa LT; Amorim A; Silva RM
Oncotarget; 2016 Jan; 7(2):1973-83. PubMed ID: 26675378
[TBL] [Abstract][Full Text] [Related]
7.
Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
[No Abstract] [Full Text] [Related]
8. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Fons NR; Sundaram RK; Breuer GA; Peng S; McLean RL; Kalathil AN; Schmidt MS; Carvalho DM; Mackay A; Jones C; Carcaboso ÁM; Nazarian J; Berens ME; Brenner C; Bindra RS
Nat Commun; 2019 Aug; 10(1):3790. PubMed ID: 31439867
[TBL] [Abstract][Full Text] [Related]
9. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.
Chowdhry S; Zanca C; Rajkumar U; Koga T; Diao Y; Raviram R; Liu F; Turner K; Yang H; Brunk E; Bi J; Furnari F; Bafna V; Ren B; Mischel PS
Nature; 2019 May; 569(7757):570-575. PubMed ID: 31019297
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
11. NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
Hong SM; Park CW; Kim SW; Nam YJ; Yu JH; Shin JH; Yun CH; Im SH; Kim KT; Sung YC; Choi KY
Oncogene; 2016 Jul; 35(27):3544-54. PubMed ID: 26568303
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
[TBL] [Abstract][Full Text] [Related]
13. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
15. A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase.
Minazzato G; Marangoni E; Fortunato C; Petrelli R; Cappellacci L; Del Bello F; Sorci L; Gasparrini M; Piacente F; Bruzzone S; Raffaelli N
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770640
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy.
Kim M; Kim H; Kang BG; Lee J; Kim T; Lee H; Jung J; Oh MJ; Seo S; Ryu MJ; Sung Y; Lee Y; Yeom J; Han G; Cha SS; Jung H; Kim HS
Theranostics; 2023; 13(14):5075-5098. PubMed ID: 37771778
[No Abstract] [Full Text] [Related]
17. Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors.
Wilsbacher JL; Cheng M; Cheng D; Trammell SAJ; Shi Y; Guo J; Koeniger SL; Kovar PJ; He Y; Selvaraju S; Heyman HR; Sorensen BK; Clark RF; Hansen TM; Longenecker KL; Raich D; Korepanova AV; Cepa S; Towne DL; Abraham VC; Tang H; Richardson PL; McLoughlin SM; Badagnani I; Curtin ML; Michaelides MR; Maag D; Buchanan FG; Chiang GG; Gao W; Rosenberg SH; Brenner C; Tse C
Mol Cancer Ther; 2017 Jul; 16(7):1236-1245. PubMed ID: 28468779
[TBL] [Abstract][Full Text] [Related]
18. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
19. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
